Terms: = Endocrine gland cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Treatment
73 results:
1. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
Wang H; Zhang C; Li Q; Tian T; Huang R; Qiu J; Tian R
BMC Cancer; 2024 Apr; 24(1):427. PubMed ID: 38589799
[TBL] [Abstract] [Full Text] [Related]
3. Mental health and diet quality after primary treatment for ovarian cancer.
Johnston EA; Veenhuizen SGA; Ibiebele TI; Webb PM; van der Pols JC;
Nutr Diet; 2024 Apr; 81(2):215-227. PubMed ID: 38192229
[TBL] [Abstract] [Full Text] [Related]
4. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic cancer Risk in Patients With Type 2 Diabetes.
Dankner R; Murad H; Agay N; Olmer L; Freedman LS
JAMA Netw Open; 2024 Jan; 7(1):e2350408. PubMed ID: 38175642
[TBL] [Abstract] [Full Text] [Related]
5. [Diagnostic Value of American Thyroid Association Guidelines,American College of Radiology Thyroid Imaging Reporting and Data System,and Chinese Thyroid Imaging Reporting and Data System Alone and Combined With BRAF
Lin Y; Luo YK; Li J; Ren XY; Wang HW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):921-928. PubMed ID: 38173102
[TBL] [Abstract] [Full Text] [Related]
6. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary Thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
7. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
Zhu Y; Liu K; Cao H; Zhu H
J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
[TBL] [Abstract] [Full Text] [Related]
8. Identification of BRAF, ccnd1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature.
Liu Z; Jin C; Zhang Y; Jiang Y; Wang J; Zheng L
World J Surg Oncol; 2023 May; 21(1):158. PubMed ID: 37221610
[TBL] [Abstract] [Full Text] [Related]
9. Anticancer Effect of Active Component of Astragalus Membranaceus Combined with Olaparib on Ovarian cancer Predicted by Network-Based Pharmacology.
Liu Y; Guo Z; Lang F; Li J; Jiang J
Appl Biochem Biotechnol; 2023 Nov; 195(11):6994-7020. PubMed ID: 36976504
[TBL] [Abstract] [Full Text] [Related]
10. Long noncoding RNA CASC9 promotes pancreatic cancer progression by acting as a ceRNA of miR-497-5p to upregulate expression of ccnd1.
Zhou J; Song G; Su M; Zhang H; Yang T; Song Z
Environ Toxicol; 2023 Jun; 38(6):1251-1264. PubMed ID: 36947456
[TBL] [Abstract] [Full Text] [Related]
11. Network-medicine approach for the identification of genetic association of parathyroid adenoma with cardiovascular disease and type-2 diabetes.
Imam N; Alam A; Siddiqui MF; Veg A; Bay S; Khan MJI; Ishrat R
Brief Funct Genomics; 2023 May; 22(3):250-262. PubMed ID: 36790356
[TBL] [Abstract] [Full Text] [Related]
12. DDTC Suppresses Ovarian cancer Development via the PI3K/AKT/mTOR Signaling Pathway.
Li M; Zhang W; Wang Y; Huang K; Sun T; Qiu Z; Yang L; Wu M; Zhang X; Zhang W
Dis Markers; 2022; 2022():1941077. PubMed ID: 35978887
[TBL] [Abstract] [Full Text] [Related]
13. Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases.
Han L; Guo X; Du R; Guo K; Qi P; Bian H
J Ovarian Res; 2022 Jun; 15(1):75. PubMed ID: 35739532
[TBL] [Abstract] [Full Text] [Related]
14. Effect of distance from target on hypopituitarism after stereotactic radiosurgery for pituitary adenomas.
Ironside N; Snyder H; Xu Z; Schlesinger D; Chen CJ; Vance ML; Hong GK; Jane JA; Sheehan JP
J Neurooncol; 2022 May; 158(1):41-50. PubMed ID: 35461378
[TBL] [Abstract] [Full Text] [Related]
15. NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
[TBL] [Abstract] [Full Text] [Related]
16. Genetics and Epigenetics of Parathyroid Carcinoma.
Marini F; Giusti F; Palmini G; Perigli G; Santoro R; Brandi ML
Front Endocrinol (Lausanne); 2022; 13():834362. PubMed ID: 35282432
[TBL] [Abstract] [Full Text] [Related]
17. PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells.
Oliveira HA; Bueno AC; Pugliesi RS; da Silva Júnior RMP; de Castro M; Martins CS
J Endocrinol Invest; 2022 May; 45(5):999-1009. PubMed ID: 34988938
[TBL] [Abstract] [Full Text] [Related]
18. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
[TBL] [Abstract] [Full Text] [Related]
19. PSMC2/ccnd1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.
Zhu D; Huang J; Liu N; Li W; Yan L
Cell Death Dis; 2021 Jul; 12(8):730. PubMed ID: 34294689
[TBL] [Abstract] [Full Text] [Related]
20. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
[TBL] [Abstract] [Full Text] [Related]
[Next]
